ReviewBiochimica et biophysica acta2011
Polycystic kidney disease: pathogenesis and potential therapies.
Review in Biochimica et biophysica acta, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 1 synthesis or guideline pooled it, 73 citations in OpenAlex.
- Predictors of autosomal dominant polycystic kidney disease progression.Journal of the American Society of Nephrology : JASN · 2014Pooled it
- A MRI-based radiomics nomogram for evaluation of renal function in ADPKD.Abdominal radiology (New York) · 2022Trial
- Baseline Characteristics and Patient-Reported Outcomes of ADPKD Patients in the Multicenter TAME-PKD Clinical Trial.Kidney360 · 2020Trial
- Estimation of Kidney Volumes in Autosomal Dominant Polycystic Kidney Disease: A Comparison Between Manual Segmentation and Ellipsoid Formula.Clinics and practice · 2025Article
- A novel CT-based radiomics approach for kidney function evaluation in ADPKD: a pilot study.Clinical kidney journal · 2025Article
- Article
- Mechanosensitive protein polycystin-1 promotes periosteal stem/progenitor cells osteochondral differentiation in fracture healing.Theranostics · 2024Article
- Metabolism-based approaches for autosomal dominant polycystic kidney disease.Frontiers in molecular biosciences · 2023Review
- AMPK and Polycystic Kidney Disease Drug Development: An Interesting Off-Target Target.Frontiers in medicine · 2022Review
- Involvement of ceramide biosynthesis in increased extracellular vesicle release inFrontiers in endocrinology · 2022Article
- Renal plasticity revealed through reversal of polycystic kidney disease in mice.Nature genetics · 2021Article
- Epithelial proliferation and cell cycle dysregulation in kidney injury and disease.Kidney international · 2021Review
- Polycystins as components of large multiprotein complexes of polycystin interactors.Cellular signalling · 2020Review
- Four-jointed knock-out delays renal failure in an ADPKD model with kidney injury.The Journal of pathology · 2019Article
- Aquaporin-3 deficiency slows cyst enlargement in experimental mouse models of autosomal dominant polycystic kidney disease.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2019Article
- Polycystin-1 regulates bone development through an interaction with the transcriptional coactivator TAZ.Human molecular genetics · 2019Article
- Newly synthesized polycystin-1 takes different trafficking pathways to the apical and ciliary membranes.Traffic (Copenhagen, Denmark) · 2018Article
- Metabolism and mitochondria in polycystic kidney disease research and therapy.Nature reviews. Nephrology · 2018Review
- Three-dimensional in vitro models answer the right questions in ADPKD cystogenesis.American journal of physiology. Renal physiology · 2018Review
- A RhoA-YAP-c-Myc signaling axis promotes the development of polycystic kidney disease.Genes & development · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Autosomal dominant polycystic kidney disease (ADPKD) is a prevalent, inherited condition for which there is currently no effective specific clinical therapy. The disease is characterized by the progressive development of fluid-filled cysts derived from renal tubular epithelial cells which gradually compress the parenchyma and compromise renal function. Current interests in the field focus on understanding and exploiting signaling mechanisms underlying disease pathogenesis as well as delineating the role of the primary cilium in cystogenesis. This review highlights the pathogenetic pathways underlying renal cyst formation as well as novel therapeutic targets for the treatment of PKD. This article is part of a Special Issue entitled: Polycystic Kidney Disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.